Long noncoding RNAs in cancer: From discovery to therapeutic targets
- PMID: 32122521
- DOI: 10.1016/bs.acc.2019.08.003
Long noncoding RNAs in cancer: From discovery to therapeutic targets
Abstract
Long noncoding RNAs (lncRNAs) have recently gained considerable attention as key players in biological regulation; however, the mechanisms by which lncRNAs govern various disease processes remain mysterious and are just beginning to be understood. The ease of next-generation sequencing technologies has led to an explosion of genomic information, especially for the lncRNA class of noncoding RNAs. LncRNAs exhibit the characteristics of mRNAs, such as polyadenylation, 5' methyl capping, RNA polymerase II-dependent transcription, and splicing. These transcripts comprise more than 200 nucleotides (nt) and are not translated into proteins. Directed interrogation of annotated lncRNAs from RNA-Seq datasets has revealed dramatic differences in their expression, largely driven by alterations in transcription, the cell cycle, and RNA metabolism. The fact that lncRNAs are expressed cell- and tissue-specifically makes them excellent biomarkers for ongoing biological events. Notably, lncRNAs are differentially expressed in several cancers and show a distinct association with clinical outcomes. Novel methods and strategies are being developed to study lncRNA function and will provide researchers with the tools and opportunities to develop lncRNA-based therapeutics for cancer.
Keywords: Cancer; Long noncoding RNAs; Next-generation sequencing; Noncoding RNAs; Oncogene; Tumor suppressor.
© 2020 Elsevier Inc. All rights reserved.
Similar articles
-
The regulatory role of long noncoding RNAs in cancer.Cancer Lett. 2017 Apr 10;391:12-19. doi: 10.1016/j.canlet.2017.01.010. Epub 2017 Jan 19. Cancer Lett. 2017. PMID: 28111137 Review.
-
Long noncoding RNAs as biotargets in cisplatin-based drug resistance.Future Oncol. 2018 Dec;14(29):3085-3095. doi: 10.2217/fon-2018-0303. Epub 2018 Nov 23. Future Oncol. 2018. PMID: 30468082 Review.
-
Long noncoding RNA in prostate, bladder, and kidney cancer.Eur Urol. 2014 Jun;65(6):1140-51. doi: 10.1016/j.eururo.2013.12.003. Epub 2013 Dec 14. Eur Urol. 2014. PMID: 24373479 Review.
-
Duodenal long noncoding RNAs are associated with glycemic control after bariatric surgery in high-fat diet-induced diabetic mice.Surg Obes Relat Dis. 2017 Jul;13(7):1212-1226. doi: 10.1016/j.soard.2017.02.010. Epub 2017 Feb 20. Surg Obes Relat Dis. 2017. PMID: 28366671
-
Profile and validation of dysregulated long non‑coding RNAs and mRNAs in ovarian cancer.Oncol Rep. 2018 Nov;40(5):2964-2976. doi: 10.3892/or.2018.6654. Epub 2018 Aug 17. Oncol Rep. 2018. PMID: 30132558
Cited by
-
A novel lipid metabolism-related lncRNA signature predictive of clinical prognosis in cervical cancer.Front Genet. 2022 Oct 17;13:1001347. doi: 10.3389/fgene.2022.1001347. eCollection 2022. Front Genet. 2022. PMID: 36324514 Free PMC article.
-
Deciphering the Non-Coding RNA Landscape of Pediatric Acute Myeloid Leukemia.Cancers (Basel). 2022 Apr 22;14(9):2098. doi: 10.3390/cancers14092098. Cancers (Basel). 2022. PMID: 35565228 Free PMC article.
-
LncRNA LOXL1-AS1 promotes proliferation and invasion and inhibits apoptosis in retinoblastoma by regulating the MAPK signaling pathway.Mol Cell Biochem. 2024 Apr;479(4):1011-1022. doi: 10.1007/s11010-023-04774-4. Epub 2023 Jun 5. Mol Cell Biochem. 2024. PMID: 37273040
-
LBX2-AS1 as a Novel Diagnostic Biomarker and Therapeutic Target Facilitates Multiple Myeloma Progression by Enhancing mRNA Stability of LBX2.Front Mol Biosci. 2021 Sep 6;8:706570. doi: 10.3389/fmolb.2021.706570. eCollection 2021. Front Mol Biosci. 2021. PMID: 34552959 Free PMC article.
-
De Novo A-to-I RNA Editing Discovery in lncRNA.Cancers (Basel). 2020 Oct 13;12(10):2959. doi: 10.3390/cancers12102959. Cancers (Basel). 2020. PMID: 33066171 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials